At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
salmeteroldrug
Likely dose
salmeterol 50 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Beta-2 Adrenergic Polymorphisms on the Bronchoprotective Effects of Regular Salmeterol Treatment in Asthma
In Brief
A clinical study evaluating salmeterol for Asthma. Completed, enrolled 30 participants across 2 sites.
Detailed Summary
The purpose of the study is to find out how well a long-acting beta agonist like salmeterol works in people with different forms of the same gene. Our hypothesis is that asthmatics with the Arg/Arg genotype will have loss of bronchoprotection against exercise-induced asthma with regular salmeterol treatment, as compared to asthmatics with the Gly/Gly genotype.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedJan 2008
Primary CompletionMay 2011
Study CompletionMar 2012
TodayJul 2026
First PostedJan 16, 2008
Enrollment StartJan 1, 2008
Primary CompletionMay 1, 2011
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 18.5 years ago
Interventions
salmeteroldrug
salmeterol 50 micrograms twice daily for 2 weeks